TriSalus Life Sciences, Inc.TLSIEarnings & Financial Report
TriSalus Life Sciences, Inc. is a clinical-stage biotechnology company focused on advancing immuno-oncology and interventional oncology solutions. It develops proprietary targeted drug delivery technologies designed to improve treatment efficacy for patients with liver, pancreatic and other hard-to-treat solid tumors, primarily operating in North American markets via partnerships with clinical care and research institutions.
Revenue
$11.6M
Gross Profit
$9.7M
Operating Profit
$-9.0M
Net Profit
$-10.8M
Gross Margin
83.5%
Operating Margin
-77.9%
Net Margin
-93.5%
YoY Growth
57.4%
EPS
$-0.96
TriSalus Life Sciences, Inc. Q3 FY2025 Financial Summary
TriSalus Life Sciences, Inc. reported revenue of $11.6M (up 57.4% YoY) for Q3 FY2025, with a net profit of $-10.8M (down 350.6% YoY) (-93.5% margin). Cost of goods sold was $1.9M, operating expenses totaled $18.7M.
Key Financial Metrics
| Total Revenue | $11.6M |
|---|---|
| Net Profit | $-10.8M |
| Gross Margin | 83.5% |
| Operating Margin | -77.9% |
| Report Period | Q3 FY2025 |
TriSalus Life Sciences, Inc. Annual Revenue by Year
TriSalus Life Sciences, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $45.2M).
| Year | Annual Revenue |
|---|---|
| 2025 | $45.2M |
| 2024 | $29.4M |
| 2023 | $18.5M |
TriSalus Life Sciences, Inc. Quarterly Revenue & Net Profit History
TriSalus Life Sciences, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $13.2M | +59.8% | $-9.8M | -73.9% |
| Q3 FY2025 | $11.6M | +57.4% | $-10.8M | -93.5% |
| Q2 FY2025 | $11.2M | +52.3% | $-8.3M | -73.9% |
| Q1 FY2025 | $9.2M | +42.0% | $-10.4M | -113.2% |
| Q4 FY2024 | $8.3M | +44.4% | $-10.1M | -122.4% |
| Q3 FY2024 | $7.3M | +41.5% | $-2.4M | -32.6% |
| Q2 FY2024 | $7.4M | +59.7% | $-4.3M | -58.8% |
| Q1 FY2024 | $6.5M | +116.4% | $-13.2M | -204.5% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $6.5M | $7.4M | $7.3M | $8.3M | $9.2M | $11.2M | $11.6M | $13.2M |
| YoY Growth | 116.4% | 59.7% | 41.5% | 44.4% | 42.0% | 52.3% | 57.4% | 59.8% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $17.9M | $32.4M | $27.5M | $24.0M | $28.6M | $41.3M | $36.5M | $35.3M |
| Liabilities | $52.8M | $56.6M | $47.9M | $49.9M | $63.0M | $60.7M | $63.2M | $69.2M |
| Equity | $-36.0M | $-25.3M | $-20.4M | $-25.9M | $-34.4M | $-19.4M | $-26.7M | $-33.9M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-10.9M | $-13.4M | $-10.8M | $-5.7M | $-4.5M | $-7.3M | $-3.7M | $-2.5M |